Actively Recruiting
Evaluating Megestrol Acetate Plus Trastuzumab Deruxtecan for Fatigue in Advanced Breast Cancer Patients
Led by Sun Yat-sen University · Updated on 2026-08-14
132
Participants Needed
2
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying whether adding Megestrol Acetate at the start of Trastuzumab Deruxtecan T-DXd treatment can help reduce fatigue in women with advanced breast cancer. This trial focuses on patients with HER2-positive, HER2-low, or HER2-ultralow advanced or metastatic breast cancer who have not previously received T-DXd. The study aims to improve quality of life by evaluating fatigue levels and safety of this combination treatment. Participants will be randomly assigned to receive either Megestrol Acetate alongside standard T-DXd therapy or a placebo with standard T-DXd. Megestrol Acetate is given orally at 160 mg on days 1 to 5 every three weeks for two cycles, while T-DXd is administered as a 5.4 mgkg intravenous infusion every three weeks. The study is double-blind and includes two treatment cycles, each lasting 28 days. During the trial, participants will be closely monitored with assessments of fatigue using the FACIT-Fatigue Scale and Brief Fatigue Inventory at multiple time points. Other evaluations include tumor response rates, patient-reported outcomes, and safety checks from the first dose until 30 days after treatment ends. The primary fatigue measurement is taken from baseline to approximately six weeks. Overall participation may last several months, with regular visits for treatment and assessments to track effects and safety.
CONDITIONS
Brief Title
Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer
Research Team
M
Meiting Chen Doctor, PhD / Doctorate
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here